Bavarian Nordic A/S

LSE:0DPB Stock Report

Market Cap: DKK 15.6b

Bavarian Nordic Valuation

Is 0DPB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0DPB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0DPB (DKK197.47) is trading below our estimate of fair value (DKK489.91)

Significantly Below Fair Value: 0DPB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0DPB?

Key metric: As 0DPB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0DPB. This is calculated by dividing 0DPB's market cap by their current earnings.
What is 0DPB's PE Ratio?
PE Ratio14x
EarningsDKK 1.12b
Market CapDKK 15.63b

Price to Earnings Ratio vs Peers

How does 0DPB's PE Ratio compare to its peers?

The above table shows the PE ratio for 0DPB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average54.2x
GNS Genus
129.2x31.5%UK£1.0b
BVXP Bioventix
21.3xn/aUK£172.2m
ERGO Ergomed
46.7x14.2%UK£701.1m
4587 PeptiDream
19.7x0.1%JP¥339.3b
0DPB Bavarian Nordic
14x3.6%DKK 15.6b

Price-To-Earnings vs Peers: 0DPB is good value based on its Price-To-Earnings Ratio (14x) compared to the peer average (56.7x).

Price to Earnings Ratio vs Industry

How does 0DPB's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0DPB 14.0xIndustry Avg. 28.1xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0DPB is good value based on its Price-To-Earnings Ratio (14x) compared to the European Biotechs industry average (28.1x).

Price to Earnings Ratio vs Fair Ratio

What is 0DPB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0DPB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14x
Fair PE Ratio19.4x

Price-To-Earnings vs Fair Ratio: 0DPB is good value based on its Price-To-Earnings Ratio (14x) compared to the estimated Fair Price-To-Earnings Ratio (19.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0DPB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 197.47
DKK 319.50
+61.8%
16.4%DKK 370.00DKK 238.00n/a4
Dec ’25DKK 195.44
DKK 319.50
+63.5%
16.4%DKK 370.00DKK 238.00n/a4
Nov ’25DKK 213.80
DKK 315.00
+47.3%
17.2%DKK 375.00DKK 230.00n/a4
Oct ’25DKK 228.73
DKK 310.80
+35.9%
15.8%DKK 375.00DKK 230.00n/a5
Sep ’25DKK 266.11
DKK 286.00
+7.5%
25.7%DKK 380.00DKK 176.00n/a5
Aug ’25DKK 188.46
DKK 263.20
+39.7%
20.3%DKK 331.00DKK 176.00n/a5
Jul ’25DKK 172.35
DKK 263.20
+52.7%
20.3%DKK 331.00DKK 176.00n/a5
Jun ’25DKK 183.58
DKK 262.00
+42.7%
21.1%DKK 331.00DKK 170.00n/a5
May ’25DKK 152.25
DKK 264.80
+73.9%
22.3%DKK 345.00DKK 170.00n/a5
Apr ’25DKK 154.95
DKK 276.80
+78.6%
20.9%DKK 345.00DKK 170.00n/a5
Mar ’25DKK 154.49
DKK 276.80
+79.2%
20.9%DKK 345.00DKK 170.00n/a5
Feb ’25DKK 155.26
DKK 292.80
+88.6%
21.1%DKK 350.00DKK 174.00n/a5
Jan ’25DKK 177.47
DKK 275.67
+55.3%
24.8%DKK 350.00DKK 174.00n/a6
Dec ’24DKK 164.06
DKK 275.67
+68.0%
24.8%DKK 350.00DKK 174.00DKK 195.446
Nov ’24DKK 138.15
DKK 279.00
+102.0%
18.1%DKK 340.00DKK 214.00DKK 213.806
Oct ’24DKK 159.06
DKK 292.29
+83.8%
21.9%DKK 407.00DKK 214.00DKK 228.737
Sep ’24DKK 150.59
DKK 292.29
+94.1%
21.9%DKK 407.00DKK 214.00DKK 266.117
Aug ’24DKK 143.37
DKK 309.14
+115.6%
22.5%DKK 424.00DKK 245.00DKK 188.467
Jul ’24DKK 195.70
DKK 367.29
+87.7%
14.8%DKK 425.00DKK 265.00DKK 172.357
Jun ’24DKK 188.32
DKK 367.29
+95.0%
14.8%DKK 425.00DKK 265.00DKK 183.587
May ’24DKK 183.99
DKK 391.71
+112.9%
17.8%DKK 480.00DKK 265.00DKK 152.257
Apr ’24DKK 196.60
DKK 391.71
+99.2%
17.8%DKK 480.00DKK 265.00DKK 154.957
Mar ’24DKK 214.00
DKK 387.33
+81.0%
19.4%DKK 480.00DKK 265.00DKK 154.496
Feb ’24DKK 212.83
DKK 400.00
+87.9%
18.9%DKK 480.00DKK 265.00DKK 155.267
Jan ’24DKK 216.60
DKK 400.57
+84.9%
18.7%DKK 480.00DKK 269.00DKK 177.477
Dec ’23DKK 242.14
DKK 400.57
+65.4%
18.7%DKK 480.00DKK 269.00DKK 164.067

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 12:04
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bavarian Nordic A/S is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter AnkersenABG Sundal Collier
Jacob LademannCarnegie Investment Bank AB
Peter VerdultCitigroup Inc